LOVAZA Drug Patent Profile

Which patents cover Lovaza, and what generic alternatives are available?

Lovaza is a drug marketed by Waylis Therap and is included in one NDA.

The generic ingredient in LOVAZA is omega-3-acid ethyl esters. There are thirteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the omega-3-acid ethyl esters profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lovaza

A generic version of LOVAZA was approved as omega-3-acid ethyl esters by GLW on April 7^th, 2014.

Summary for LOVAZA

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for LOVAZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LOVAZA	Capsules	omega-3-acid ethyl esters	1 g	021654	3	2008-11-10

US Patents and Regulatory Information for LOVAZA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Waylis Therap	LOVAZA	omega-3-acid ethyl esters	CAPSULE;ORAL	021654-001	Nov 10, 2004	AB	RX	Yes	Yes

International Patents for LOVAZA

See the table below for patents covering LOVAZA around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	1523541	PROCÉDÉ ET FLUIDE VOLATILE REDUISANT LES POLLUANTS ENVIRONNEMENTAUX PRÉSENTS DANS DES GRAISSES OU DES HUILES, SUPPLÉMENT DIETETIQUE, ET PRODUIT ALIMENTAIRE POUR ANIMAUX (A PROCESS FOR DECREASING ENVIRONMENTAL POLLUTANTS IN AN OIL OR A FAT, A VOLATILE ENVIRONMENTAL POLLUTANTS DECREASING WORKING FLUID, A HEALTH SUPPLEMENT, AND AN ANIMAL FEED PRODUCT)
Japan	3905538
Cyprus	1109971
United Kingdom	2221843	FATTY ACID COMPOSITION

Summary:
LOVAZA (icosapent ethyl) is an EPA (eicosapentaenoic acid) ethyl ester approved by the FDA for reducing cardiovascular risk in adults with elevated triglycerides. It is marketed primarily by amending its label to include cardiovascular risk reduction following the REDUCE-IT trial results. The drug represents a significant segment in the omega-3 market, with a focus on cardiometabolic health. Investment analysis hinges on approval stability, market penetration, and competitive landscape, notably against other omega-3 formulations and emerging lipid-lowering therapies.

---

What Are the Core Pharmaceutical Fundamentals of LOVAZA?
LOVAZA’s active ingredient is icosapent ethyl, a high-purity EPA derivative. It targets patients with triglycerides ≥150 mg/dL and established cardiovascular disease, or diabetes with additional risk factors. The drug’s labeled indication expanded in 2019, emphasizing cardiovascular risk reduction, based on the REDUCE-IT trial where primary and secondary endpoints showed a 25% relative risk reduction through a 4 g daily dosage.

Regulatory Status and Approvals:

• Approved in the U.S. since July 2012.
• Newly labeled in 2019 for cardiovascular risk reduction, based on REDUCE-IT results.
• Similar formulations and approvals exist in select markets, including Japan and the EU, with varying indications.

Market Dynamics and Sales:

• U.S. sales reached approximately $950 million in 2022, with growth driven by expanded indication and increased cardiovascular patient awareness.
• Market penetration remains concentrated among cardiologists and endocrinologists; insurance coverage and formulary inclusion influence uptake.
• Generic competition is limited owing to the patent estate; the original formulation has patent extensions until late 2020s or early 2030s (subject to legal challenges).

Competitive Landscape:

• Other omega-3 products (e.g., prescription-strength EPA/DHA formulations like Vascepa, Omega-3 acid ethyl esters).
• Emerging lipid-lowering agents, such as PCSK9 inhibitors and next-generation therapies, may erode market share.
• The success of LOVAZA depends on differentiating its cardiovascular benefit claim and securing insurance reimbursement.

Research and Development Outlook:

• Ongoing studies examine LOVAZA’s role in secondary prevention and broader cardio-metabolic conditions.
• Additional indications, if approved, could expand market size.

Financial Considerations:

• R&D expenses aligned with maintaining regulatory exclusivity and potential pipeline expansion.
• Pricing strategy hinges on reimbursement negotiations; premium positioning linked to clinical benefits contributes to higher margins.
• Patent life and legal protections are pivotal; patent expiry risks must be mitigated through formulation or method patents and litigation.

Investment Risks and Opportunities:

• Risks: Patent expiration, competition from emerging therapies, regulatory changes, market saturation.
• Opportunities: Growth in high-risk cardiovascular populations, expansion to global markets, potential label extensions.

---

Key Takeaways:

• LOVAZA’s core value resides in its FDA-approved cardiovascular risk reduction claim, supported by the REDUCE-IT trial.
• The market remains lucrative but competitive, with limited generic threats until patent expiration.
• Future approval for expanded indications and global market entry coulddrive growth.
• Ongoing research and evolving lipid therapies pose both challenge and opportunity.
• Strategic patent management and reimbursement negotiations are critical for sustained profitability.

---

Frequently Asked Questions:

Last updated: February 3, 2026

1. What differentiates LOVAZA from other omega-3 drugs?
   LOVAZA’s differentiation centers on its high-purity EPA composition and the FDA-approved cardiovascular risk reduction label based on the REDUCE-IT study.

2. How long is the patent protection for LOVAZA?
   Patent protections extend into the late 2020s, with potential extensions; however, legal challenges and generic entrants could alter this timeline.

3. What is the expected market growth for LOVAZA?
   Market growth depends on expanding indications, penetration among cardiovascular patients, and the competitive landscape. Historically, U.S. sales have grown at a CAGR of approximately 10% over recent years.

4. Are there regulatory hurdles that could impact LOVAZA’s future?
   Yes; changes in lipid therapy regulations, patent disputes, or safety concerns could influence its market position.

5. What are the main clinical trials supporting LOVAZA’s cardioprotective claims?
   The REDUCE-IT trial (2018) is the primary evidence, showing significant reduction in major adverse cardiovascular events among high-risk patients with elevated triglycerides.

---

Sources:
[1] FDA label for LOVAZA.
[2] Amarin Corporation financial reports, 2022.
[3] REDUCE-IT trial publication.
[4] IMS Health drug sales database, 2022.
[5] European Medicines Agency approval summaries.